Payment overview · 2025
General Payments
$81.14
4 reported records · 2 companies
Healthcare provider profile · identity verified
Martin James Murphy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WINSTON SALEM, NC · NPI 1467428631
Verified facts
What the public records show
CMS Open Payments records show Martin James Murphy, MD received $81.14 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.87 | 65.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.27 | 34.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.14 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1000 | 271 |
| Lisinopril | Lisinopril | 853 | 227 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 813 | 241 |
| Alprazolam | Alprazolam | 801 | 192 |
| Atorvastatin Calcium | Atorvastatin Calcium | 767 | 207 |
| Simvastatin | Simvastatin | 695 | 193 |
| Losartan Potassium | Losartan Potassium | 680 | 189 |
| Omeprazole | Omeprazole | 617 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 592 | 162 |
| Hydrochlorothiazide | Hydrochlorothiazide | 421 | 129 |
| Metformin Hcl | Metformin Hcl | 420 | 130 |
| Tamsulosin Hcl | Tamsulosin Hcl | 384 | 116 |
| Gabapentin | Gabapentin | 383 | 116 |
| Sertraline Hcl | Sertraline Hcl | 362 | 92 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 345 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 97 |
| Furosemide | Furosemide | 325 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 310 | 94 |
| Allopurinol | Allopurinol | 294 | 82 |
| Lovastatin | Lovastatin | 257 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 71 |
| Atenolol | Atenolol | 238 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 233 | 82 |
| Glipizide Er | Glipizide | 229 | 72 |
| Potassium Chloride | Potassium Chloride | 229 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 58 |
| Eliquis | Apixaban | 206 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 68 |
| Tramadol Hcl | Tramadol Hcl | 185 | 47 |
| Montelukast Sodium | Montelukast Sodium | 154 | 44 |
| Clonazepam | Clonazepam | 151 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 41 |
| Metformin Hcl Er | Metformin Hcl | 142 | 43 |
| Carvedilol | Carvedilol | 133 | 37 |
| Glipizide | Glipizide | 131 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 30 |
| Donepezil Hcl | Donepezil Hcl | 126 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 109 | 30 |
| Mirtazapine | Mirtazapine | 105 | 22 |
| Meloxicam | Meloxicam | 102 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 31 |
| Finasteride | Finasteride | 97 | 34 |
| Bupropion Xl | Bupropion Hcl | 92 | 22 |
| Jardiance | Empagliflozin | 89 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 25 |
| Trazodone Hcl | Trazodone Hcl | 83 | 19 |
| Pregabalin | Pregabalin | 82 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 24 |
| Ozempic | Semaglutide | 81 | 11 |
| Valsartan | Valsartan | 81 | 22 |
| Ezetimibe | Ezetimibe | 80 | 23 |
| Famotidine | Famotidine | 80 | 24 |
| Meclizine Hcl | Meclizine Hcl | 76 | 33 |
| Ibuprofen | Ibuprofen | 74 | 25 |
| Celecoxib | Celecoxib | 71 | 22 |
| Diazepam | Diazepam | 69 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 63 | 29 |
| Spironolactone | Spironolactone | 62 | 19 |
| Warfarin Sodium | Warfarin Sodium | 61 | 16 |
| Xarelto | Rivaroxaban | 60 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 50 |
| Amoxicillin | Amoxicillin | 55 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 31 |
| Lorazepam | Lorazepam | 52 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 16 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Prednisone | Prednisone | 42 | 20 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 20 |
| Synthroid | Levothyroxine Sodium | 40 | 13 |
| Chlorthalidone | Chlorthalidone | 38 | 11 |
| Gemfibrozil | Gemfibrozil | 38 | 12 |
| Nitroglycerin | Nitroglycerin | 38 | 21 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Propranolol Hcl | Propranolol Hcl | 34 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Clotrimazole | Clotrimazole | 32 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Inderal La | Propranolol Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Glimepiride | Glimepiride | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.14 · 4 records | Novo Nordisk Inc | Dexcom G6 Transmitter | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error